Blood cell clues may explain why some kidney patients relapse

NCT ID NCT06994468

Completed Knowledge-focused Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at blood samples from 48 people with membranous nephropathy, a kidney disease. Researchers used a special test to measure immune cells (B cells) that target a protein called PLA2R. The goal is to see how these cells change after treatment with B-cell depleting drugs, and whether they can predict who will stay in remission or relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors understand why some patients relapse or don't respond to B-cell depleting therapies, potentially guiding better treatment choices.
What could go wrong: This is a small, observational study that does not test a new treatment. It only looks at stored blood samples, so results may not apply to all patients or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEMBRANOUS NEPHROPATHY

Contacts and locations

Locations

Clinical Research Centre for Rare Diseases Aldo e Cele Daccò

Ranica, BG, 24020, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.